Aura Biosciences (NASDAQ:AURA) is a biotech company dedicated to developing innovative treatments for cancer patients, with a strong focus on ocular melanoma. By leveraging their unique virus-like drug conjugate (VDC) technology, Aura aims to create targeted therapies that can improve clinical outcomes for patients suffering from this rare and life-threatening disease. The company is deeply committed to pushing the boundaries of cancer therapy, working on projects that could potentially revolutionize the way ocular tumors are treated. Aura's primary objective is to bring safe, effective, and breakthrough treatments to market, offering new hope to those battling cancer.